Avelumab and Merkel Cell Carcinoma: Understanding the Relationship

From General Health to Occupational Exposure Concerns

For decades, public health communication has centered on general wellness and the prevention of common ailments, with a strong emphasis on lifestyle factors and environmental influences. This legacy framework has served as the foundation for understanding how external conditions can affect human health, from workplace safety to broader community well-being. Within this context, the transition from general health awareness to more specific occupational exposure concerns represents a natural evolution of inquiry. As industrial processes have become more complex, attention has shifted toward identifying and mitigating risks associated with specific substances encountered in professional settings. The mass production environment, in particular, presents unique challenges where workers may encounter materials not commonly present in everyday life. This has led to focused investigations into how certain pharmaceutical agents, when used therapeutically, might interact with occupational histories. The case of avelumab, a monoclonal antibody employed in oncology, exemplifies this intersection: its administration in patients with prior or ongoing workplace exposures raises important questions about potential synergistic effects. Understanding the relationship between avelumab exposure and subsequent health outcomes, including malignancy risk, requires careful consideration of both the drug's mechanism and the patient's occupational background. This pivot from general health principles to targeted exposure analysis underscores the need for nuanced risk assessment in modern medical practice.

Avelumab: Mechanism and Approved Use in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). The approval was based on the two-part, single-arm, phase II JAVELIN Merkel 200 trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for use in this indication, and it is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).

Merkel Cell Carcinoma: Etiology and Risk Factors

Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus, with approximately 80% of cases caused by the human Merkel cell polyomavirus and the remaining 20% induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence rate of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors, including avelumab and pembrolizumab, offer durable responses and significant clinical benefit, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy, and 50% of patients do not respond or develop immune-related adverse events due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/35877101/; https://pubmed.ncbi.nlm.nih.gov/34445385/).

Causation and Risk: Avelumab as Treatment, Not Cause

The mechanistic pathway linking avelumab to Merkel cell carcinoma is not one of causation but of therapeutic intervention. Avelumab is used to treat MCC by blocking PD-L1, thereby enhancing the immune system's ability to recognize and attack cancer cells. The evidence does not indicate that avelumab causes MCC; rather, it is a treatment for the disease. The risk narrative here concerns the adequacy of warnings regarding avelumab's use in MCC patients, particularly those who are refractory to the drug. For avelumab-refractory patients, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). Studies have investigated the use of combined ipilimumab and nivolumab in avelumab-refractory MCC. In a retrospective study at three academic sites in Germany, three out of five patients with metastatic MCC refractory to avelumab responded to combined ipilimumab and nivolumab according to RECIST 1.1 criteria (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported on ipilimumab plus nivolumab in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). Another retrospective study noted that despite advances in systemic therapy, about 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Timeline and Harm Considerations for Affected Patients

Causation-related considerations for affected patients focus on the timeline between exposure to avelumab and documented harm. Since avelumab is a treatment for MCC, the harm of concern is not the development of MCC but rather the lack of response or progression of the disease while on therapy. The evidence indicates that avelumab can be effective, with objective responses in about one-third of chemotherapy-refractory patients (https://pubmed.ncbi.nlm.nih.gov/29799096/). However, for those who do not respond or become refractory, the timeline to progression can vary. The studies reviewed do not provide specific data on the exact timeline between avelumab exposure and harm, but they highlight that a significant proportion of patients may not benefit from the drug. The adequacy of warnings regarding avelumab and MCC should include information about the risk of non-response and the potential need for alternative therapies, such as combined ipilimumab and nivolumab, which have shown activity in avelumab-refractory cases (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/). In summary, the evidence supports that avelumab is an approved and effective treatment for metastatic MCC, but it is not a cause of the disease. The risk for patients lies in the possibility of non-response or progression, which occurs in about half of treated individuals. Warnings should adequately communicate this risk and the availability of subsequent treatment options. The timeline between exposure and harm is variable and depends on individual patient response.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does avelumab cause Merkel cell carcinoma?

No, avelumab does not cause Merkel cell carcinoma. It is a treatment for the disease. Avelumab is an immune checkpoint inhibitor that targets PD-L1 to help the immune system attack cancer cells. The evidence shows it is effective in about one-third of chemotherapy-refractory patients, but it is not a causative agent.

What are the risks of avelumab treatment for Merkel cell carcinoma?

The main risk is that approximately 50% of patients with advanced MCC do not respond or progress on therapy. For those who are refractory, alternative treatments like combined ipilimumab and nivolumab may be considered. Warnings should include the possibility of non-response and the need for subsequent therapies.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.